{"nctId":"NCT00536744","briefTitle":"Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers","startDateStruct":{"date":"2007-10"},"conditions":["Diabetic Foot Ulcers"],"count":206,"armGroups":[{"label":"Active PACE application - 4 applications","type":"ACTIVE_COMPARATOR","interventionNames":["Device: acoustical pulse energy (extracorporeal shockwave)"]},{"label":"Inactive, non-energy application","type":"SHAM_COMPARATOR","interventionNames":["Other: Sham"]}],"interventions":[{"name":"acoustical pulse energy (extracorporeal shockwave)","otherNames":["dermaPACE"]},{"name":"Sham","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Major Inclusion Criteria:\n\n* Male or female ≥ 18 years of age\n* Diabetes mellitus\n* One or more chronic foot ulcers (only one will be treated) that are located in the ankle area or below that has persisted a minimum of 30 days prior to the Screening visit\n* HbA1c ≤ 12%\n* Diabetic Foot Ulcers ≥ 1 cm2 and ≤ 16 cm2\n* Ulcer Grade I or II, Stage A according to the University of Texas Diabetic Wound Classification system\n* Ankle Brachial Index (ABI) ≥ 0.7 and ≤ 1.2, OR toe pressure \\> 50 mmHg, OR tcPO2\\> 40 mmHg.\n\nMajor Exclusion Criteria:\n\n* Subject is morbidly obese (Body Mass Index ≥ 40)\n* Subjects on dialysis\n* Diagnosis of foot ulcer involving osteomyelitis\n* Has evidence of prior ulcer in the same area\n* Multiple diabetic foot ulcers on the foot that either are connected by fistulas or are within 5 cm of the target ulcer\n* Subject's foot ulcer intended for study application has decreased in volume by 50% or more at the end of the two-week Run-in period as compared to the Screening visit.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Primary Variable for Effectiveness of the dermaPACE Device Will be Assessed by Comparing the Incidence of Complete Wound Closure of the dermaPACE and Control Groups 12 Weeks Post Initial Application.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Wound Closure, Wound Closure Area and Volume Between Active and Control 12 Weeks Post Initial Application, Subject Pain Assessment Between Active and Control 24 Weeks Post Initial Application","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":34,"n":107},"commonTop":["infections","target site pain, irritation, illnesses","anorexia, dehydration, diabetes related conditions","non-ulcer injuries","blisters, dermatitis, non-ulcer skin conditions"]}}}